登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C24H34N2O5
化学文摘社编号:
分子量:
430.54
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1
SMILES string
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O
InChI key
VXFJYXUZANRPDJ-WTNASJBWSA-N
grade
pharmaceutical primary standard
API family
trandolapril
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Trandolapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Trandolapril is an ACE inhibitor.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
M Miyazaki et al.
American journal of hypertension, 8(10 Pt 2), 63S-67S (1995-10-01)
This article discusses the pharmacologic basis on which trandolapril exhibits a more potent and longer-lasting antihypertensive effect than its chemical prototype enalapril. Our studies have shown that 1) trandolapril and its active metabolite trandolaprilat are more lipophilic than enalapril and
M Buksa
Medicinski arhiv, 54(2), 103-106 (2000-08-10)
Left ventricle systolic dysfunction and congestive heart failure after AMI are still a great problem in cardiology. Introduction of angiotensin converting enzyme (ACE) inhibitors after AMI has been a new step in therapy of the left ventricle systolic disfunction. Some
C A Gaillard et al.
American heart journal, 125(5 Pt 2), 1542-1546 (1993-05-01)
In this article the clinical experiences with the new non-sulfhydryl angiotensin-converting enzyme inhibitor trandolapril are reviewed. The drug lowers blood pressure effectively in patients with mild-to-severe hypertension including elderly and obese patients. Distinguishing features of the compound are its long
L R Wiseman et al.
Drugs, 48(1), 71-90 (1994-07-01)
Trandolapril is a non-sulfhydryl prodrug which, after oral administration, is hydrolysed in the liver to its active diacid, trandolaprilat. Trandolaprilat inhibits the angiotensin converting enzyme (ACE) and displays similar pharmacodynamic properties to other ACE inhibitors, improving haemodynamic and cardiac parameters
D C Peters et al.
Drugs, 56(5), 871-893 (1998-11-26)
Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of patients with hypertension and congestive heart failure (CHF), and after myocardial infarction (MI). Trandolapril is a nonsulfhydryl prodrug that is hydrolysed to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持